Introduction
Decreasing activation of the renin-angiotensinaldosterone system (RAAS) is an essential target of the pharmacological treatment of patients with congestive heart failure (CHF). Several large, randomised, placebo-controlled trials have shown that angiotensin converting enzyme (ACE) inhibition enhances life expectancy and alleviates symptoms in patients with CHF and with acute myocardial infarction and left ventricular (LV) systolic dysfunction. [1] [2] [3] The exact mechanisms that mediate the clinical benefits of ACE inhibitors are still poorly understood, although it is generally assumed that the benefits are somehow related to decreased activity of the RAAS and thereby reduced levels of tissue and plasma angiotensin II (Ang II).
ELITE-2 trial
During long-term administration of steady doses of ACE inhibitors to compliant patients, Ang II plasma levels rise above baseline values in at least one third of patients with CHF. 4, 5 This observation that was initially made in hypertensive patients, has been labelled 'escape from ACE inhibition' and is often referred as 'ACE escape'. 6 The return of symptoms in patients with CHF treated with ACE inhibitors and the limited and transient benefits of ACE inhibitors in this patient population have been conveniently attributed to the ACE escape phenomenon. 3 In addition, the ACE escape phenomenon has fuelled a huge interest in angiotensin II type 1 receptor (AT 1 -receptor) antagonists since they provide sustained and insurmountable blockade of AT 1 -receptors with time. 7 The clinical effects of ACE inhibition were compared with those of AT 1 -receptor blockade in the Evaluation of Losartan In The Elderly trial (ELITE-2). 8 ACE inhibitor-naive patients older than 60 years with CHF were randomised to receive captopril (150 mg) or losartan (50 mg) daily. Preliminary results of the ELITE-2 trial indicate that the effects of captopril and losartan on mortality are not statistically different. At first glance, comparable effects of captopril and losartan on mortality suggest that escape from ACE inhibition may not be clinically relevant. With time, one would expect AT 1 -receptor blockade to be increasingly beneficial as it negates the detrimental effects of spontaneously rising levels of Ang II. In fact the opposite was observed as time evolved. Patients randomised to losartan were more likely to die than those randomised to captopril (280 vs 250 deaths). 9 However, definite conclusions cannot be drawn from the ELITE-2 trial since a daily dose of 50 mg of losartan does not provide either complete or sustained blockade of AT 1 -receptors over a 24-hour period. 10 In that regard, the clinical equivalence between a high dose of an ACE inhibitor (captopril 150 mg daily) and a low dose of an AT 1 -receptor antagonist (losartan 50 mg daily) suggests that full AT 1 -receptor blockade may in fact be superior to ACE inhibition.
Combined AT 1 -receptor blockade and ACE inhibition approach
Independent of the dose issue, the negative results of the ELITE-2 trial, that was powered to detect a 20% superiority of losartan over captopril, have shifted the interest of clinicians to use AT 1 -receptor antagonists (AIIAs) in symptomatic patients with CHF who are already treated with ACE inhibitors. 7 Small studies have demonstrated the haemodynamic and clinical benefits of combining AIIAs and ACE inhibitors in patients with CHF. 11, 12 Addition of valsartan at a dose of 160 mg twice daily produced sustained improvement in LV systolic performance over a four week period as evidenced by a decreased LV filling pressure and a maintained cardiac output. 12 Of note (and particularly relevant to the results of ELITE-2 trial) a lower dose of valsartan (80 mg) failed to produce improvement in LV systolic performance. Blockade of the AT 1 -receptor is associated with a five-fold increase in Ang II plasma levels presumably due to interruption of the feedback controls of the RAAS. 7 The observation that, after AT 1 -receptor blockade, plasma levels of Ang II do not increase in patients who are already treated with ACE inhibitors represents one of the potential advantages of combining ACE inhibition and AT 1 -receptor blockade to lower RAAS activity in patients with CHF. 12 Concurrent administration of an AIIA protects the receptor from newly formed Ang II when the ACE inhibitor dissociates from the converting enzyme. 13 This dissociation is a competitive process that mostly depends on tissue level of angiotensin I (Ang I).
We have demonstrated the benefits of AT 1receptor blockade on functional capacity in a six month randomised, placebo-controlled study that involved a concerted effort to reach maximally recommended or tolerated doses of ACE inhibitors prior to randomisation, to losartan 50 mg daily or to placebo. 11 After six months, all patients randomised to losartan had subjectively improved by at least one NYHA functional class and objectively by increase in peak aerobic capacity greater than 2.0 ml/kg/min, while none of the patients randomised to placebo experienced an improvement in functional class or peak aerobic capacity. In fact, mean peak aerobic capacity tended to decrease in patients randomised to placebo. This study clearly establishes the clinical benefits of adding AT 1 -receptor blockade to what is presently considered optimal doses of ACE inhibitor i.e. 40 mg daily of fosinopril, lisinopril, or enalapril or 150 mg daily of captopril. The benefits of AT 1receptor antagonism were demonstrated with a daily dose of 50 mg of losartan. As discussed with the results of the ELITE-2 trial, higher doses of losartan may completely block the AT 1 -receptor for 24 hours and presumably result in greater clinical benefits. Surprisingly, the relationship between the clinical benefits of AIIAs and the level of AT 1 -receptor blockade that they provide has never been studied in patients with hypertension or CHF.
The positive results obtained with the combination of ACE inhibitor and AIIA in patients with CHF are consistent with the additive effects of combined ACE inhibition and AT 1 -receptor blockade on blood pressure and renin release in sodium-depleted normotensive subjects, and with the results of the Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) pilot trial. 14, 15 In this trial, combined ACE inhibition and AT 1 -receptor blockade prevented LV dilatation and lowered brain natriuretic peptides (BNP) plasma levels more than either intervention alone. 15 Synthesis and release of BNP are stimulated by LV wall tension and plasma BNP levels are used to identify asymptomatic patients with LV dysfunction and to guide therapy in patients with symptomatic LV systolic dysfunction. 16
Survival trials of AT 1 -receptor blockade in patients treated with ACE inhibitors
The effects of AT 1 -receptor blockade on mortality in patients with CHF who are treated with ACE inhibitors (at doses generally used in practice) are currently being investigated in two large, randomised, placebo-controlled studies.The Valsartan Heart Failure Trial (Val-HeFT) has enrolled more than 4000 patients.The results of Val-HeFT should be presented at the American Heart Convention this year. A daily dose of 320 mg of valsartan is apparently extremely well tolerated by patients who are already treated with ACE inhibitors. The second trial, the arm of the CHARM trial that involves randomisation of patients with symptomatic LV systolic dysfunction to candesartan (16-32 mg) or to placebo, has also completed enrollment. On the basis of the studies discussed above and experimental data, one expects that combining AT 1 -receptor blockade to ACE inhibition is likely to reduce mortality of patients with CHF. The reduction of 20% or greater that needs to be observed in order to reach statistical significance in the Val-HeFT trial is perhaps optimistic.
An important issue is that none of these trials require investigators to attain maximally recommended or tolerated doses of ACE inhibitor prior to enrolling. The doses of ACE inhibitors currently prescribed by most physicians are notoriously low. Underdosage of ACE inhibitors greatly increases the likelihood that the CHARM and Val-HeFT trials will be positive. A critical question regarding the effects of combined therapy with AIIAs and ACE inhibitors on mortality in patients with CHF is the level of RAAS activity at baseline. Whether additional AT 1 -receptor blockade can reduce mortality in patients that already treated with maximally recommended doses of ACE inhibitors will not be answered by the CHARM or Val-HeFT trials. Experimental data in spontaneously hypertensive rats (SHRs) suggest that a combination of low dose AIIA and ACE inhibitor is more effective than higher doses of either therapy alone. 13 Moreover, current experience with AIIAs suggests that these agents are extremely well tolerated and are associated with significantly fewer side-effects than the average doses of ACE inhibitors investigated in most trials. Thus, based on safety, the choice between increasing doses of ACE inhibitors or combining low doses of ACE inhibitors and AIIAs may be purely academic, since patients will overwhelmingly prefer a medical regimen with fewer side-effects. Nevertheless, in an era when patients with symptomatic CHF are asked to take an inordinate number of pills, this issue is not only related to health care cost but also to quality of life. Moreover, the fewer pills a patient is asked to take, the greater the likelihood of compliance.The issue of combining low doses of two therapies versus obtaining the maximal clinical benefits from one single therapy is unlikely to be solved by algorithms derived from the results of large randomised clinical trials. It will probably require multiple dose adjustments of each therapy before adding the other therapy, with close monitoring of side-effects in individual patients. This time consuming approach may not be feasible in an era of managed care.
Level of inhibition of ACE achieved by current doses of ACE inhibitors
The added benefits of AT 1 -receptor blockade in patients with CHF treated with recommended doses of ACE inhibitors suggest that continuous Ang II formation occurs despite compliance with ACE inhibitor therapy. Several mechanisms may be responsible for this. Recommended doses of ACE inhibitors may result in incomplete ACE inhibition when the RAAS is markedly activated in patients with decompensated CHF. Alternatively, enzymatic pathways other than ACE may contribute to Ang II generation. Accordingly we have studied the level of ACE inhibition achieved in 42 patients, EDITORIAL REVIEW known to be compliant with their medical regimen by documentation of a therapeutic level of digoxin who were treated with maximally recommended doses of ACE inhibitors for at least three months. 17 Lisinopril, enalapril, or fosinopril (40 mg daily) or captopril (150 mg daily) were considered to be maximally recommended doses.The level of ACE inhibition was assessed by the pressure response to ascending doses of exogenous Ang I at doses sufficient to increase systolic radial artery pressure by >20 mmHg. The pressure response to Ang I depends on the conversion of Ang I to Ang II. In the intravascular space, conversion to Ang II is mediated exclusively by circulating and endothelium-bound ACE. 18 Thus, the pressure response to Ang I reflects ACE activity within the intravascular lumen and thereby the level of inhibition achieved by ACE inhibitors. To assess the complete inhibition of ACE, the pressure response to Ang I was measured before and after administration of an insurmountable AIIA, valsartan at a dose of 80 mg. 19 In 11 patients, the pressure response to Ang I was also evaluated after treatment with twice the maximally recommended doses of ACE inhibitors.The pressure responses to ascending doses of Ang I that were measured 12 hours after administration of 40 mg fosinopril (in 22 patients) or lisinopril (in 10 patients), six hours after administration of 40 mg enalapril (in six patients) and three hours after administration of 50 mg captopril (in the remaining four patients). In all patients, the pressure response to ascending doses of exogenous Ang I was significantly lower after administration of 80 mg valsartan. The pressure response to ascending doses of exogenous Ang I was variable from patient to patient. Some patients failed to raise radial artery pressure in response to Ang I while others experienced substantial increases in radial systolic pressure. The variability in the pressure responses to Ang I was not related to the duration of therapy with ACE inhibitors, ranging from 3 to 120 months. Thus, contrary to previous reports, time may not be a major determinant of escape from ACE inhibition. In the 11 patients who were treated with 80 mg lisinopril or fosinopril for one week, the pressure responses to ascending doses of Ang I were no longer affected by administration of valsartan.Thus, maximally recommended doses of ACE inhibitors do not completely inhibit converting enzyme in patients with CHF. Independent of Ang II generation by enzymatic pathways other than ACE, partial inhibition of ACE may contribute to continuous Ang II generation in patients treated with what is currently considered maximal doses of ACE inhibitors. The fact that merely doubling the dose of ACE inhibitor leads to complete ACE inhibition, confirms that in the intravascular space Ang II formation is exclusively generated by ACE without any contribution by non-ACE pathways. The level of inhibition of ACE achieved in the interstitial space and tissues cannot be estimated by the present data. Experimental data suggest that inhibition of ACE is achieved at much lower doses of ACE inhibitors in the intravascular space than in the interstitial space. 20 Doses of ACE inhibitors that fail to completely prevent formation of Ang II in the intravascular space are unlikely to completely abolish Ang II formation in the interstitial space.
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In summary, inhibition of ACE is only partial in patients with CHF treated with doses of ACE inhibitors that are currently considered maximal. Merely doubling the maximal dose of ACE inhibitor is sufficient to achieve complete inhibition of ACE. The clinical correlates of incomplete inhibition of ACE are currently poorly known in patients with CHF. 21 Patients whose ACE is only partially inhibited as evidenced by increasing levels of Ang II during long-term administration of ACE inhibitors seem to have a poorer clinical course. Addition of AIIAs to recommended doses of ACE inhibitors symptomatically improves these patients.Whether it also improves life expectancy remains to be demonstrated. Finally, whether increasing the doses of ACE inhibitors above those currently recommended can achieve the same clinical benefits as addition of an AIIA needs to be investigated. Common clinical experience suggests that concurrent administration of low doses of ACE inhibitors with conventional doses of AIIAs may be better tolerated than high doses of ACE inhibitors.
